Sandostatin (octreotide acetate) — United Healthcare

Initial criteria

• Diagnosis of meningioma
• Disease is surgically inaccessible
• AND
• Disease is recurrent OR disease is progressive
• AND
• Radiation is not possible

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Sandostatin therapy

Approval duration

12 months